Biopharmaceutical News Week 39
Acquisitions /mergers/joint-ventures
Aduro Biotech (Berkeley, CA, USA) acquires BioNovion (Oss, The Netherlands), a company dedicated to antibodies and checkpoint inhibitors for $32.5 million: about $16 million in cash and $16 million in stock as well as subsequent regulatory milestones.
Business
Regeneron Pharma will receive $17 million funding from US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture a monoclonal antibody treatment for Ebola infection.
Merck KGaA and Pfizer have entered a three party agreement with Dako (Glostrup,Denmark) to discover and develop companion diagnostic for avelumab. Avelumab is a checkpoint inhibitor that blocks the interaction of PD-L1 with its receptor PD-1, potentially restoring effective anti-tumour T-cell responses. The three-party agreement is focused on development of companion diagnostics to assess PD-L1 protein expression levels in tumour tissue and its microenvironment. Financial terms of the deal were not disclosed.
Biogen enters into a five-year collaboration with BioMotiv to discover and develop new neuroscience focused treatments. BioMotiv is the accelerator of the Harrington Project for Discovery & Development, a project centered at Cleveland’s University Hospitals. Under the terms of the agreement, BioMotiv will receive $15 million over five years, and Biogen will get the exclusive rights for neuroscience programs arising from the partnership.
AstraZeneca makes preclinical data for more than 50 drugs public, as part of a crowd-sourcing challenge to find new and best cancer drug combinations. The company is releasing results from around 11,500 tested drug combinations measuring cell viability over 118 therapies and 85 cancer cell lines, and monotherapy drug response data for each drug and cell lines. In parallel, the Wellcome Trust Sanger Institute is also making genomic data available for the same cell lines, offering researchers a unique data set from which to seek out combinations with the most synergistic potential.
Boehringer Ingelheim has finalized the crowd-sourced chronic obstructive pulmonary disease (COPD) R&D team it has put together with BioMed X Innovation Center (Heidelberg, Germany). The initiative is an attempt by Boehringer to tap into expertise outside of its own R&D to better understand the epigenetics of COPD.
Approval of drugs, vaccines, diagnostics and devices
US FDA approves Taiho Oncology’s Lonsurf, a new combination therapy for the treatment of colorectal cancer. The drug combines an anticancer drug called trifluridine, able to interfere with DNA function, with tipiracil hydrochloride, which maintains blood concentration of the former and is already approved in Japan.
European Regulators have approved Keryx Biopharmaceutical’s Fexeric (a ferric citrate coordination complex) for the treatment of hyperphosphatemia in both non-dialysis and dialysis chronic kidney disease patients. The drug got US FDA approval in September last year under the brand name Auryxia, but only for patients on dialysis.
St Jude Medical (St Paul, MIN, USA) obtains CE mark for its new Infinity Deep Brain Stimulation (DBS) system. DBS systems include a surgically-implanted neurostimulator, which generates the electrical pulses and thin wires called leads that carry the pulses to the brain to determine the irregular nerve signals responsible for many of the symptoms of movement disorders in patients suffering from Parkinson's disease, tremor and dystonia, a disorder that causes involuntary muscle contractions.
Drugs at clinical stage
US FDA gives Pfizer and Merck KGaA’s avelumab, an anti-PD-L1 antibody, Orphan Drug designation for the treatment of Merkel cell carcinoma, a rare and aggressive type of skin cancer.
Pfizer’s XELJANG (tofacitinib citrate) was successful in two late-stage studies in ulcerative colitis in achieving its primary efficacy endpoints at week 8. Tofacitinib is a Janus kinase (JAK) inhibitor which blocks cytokine signaling.
Novo Nordisk’s long acting GLP-1 analogue, semaglutide, was more active than AstraZeneca’s Bydureaon (exenatide-extended–release for injectable suspension) in lowering HBA1c levels in type diabetic patients. The study assessed the safety and efficacy of 1.0 mg semaglutide compared to 2.0 mg exenatide once-weekly for 56 weeks in 813 patients with type 2 diabetes. The trial successfully achieved its primary endpoint of showing the superiority of semaglutide in lowering HbA1c levels. 66% of patients treated with semaglutide achieved the treatment target of HbA1c below 7% compared to 40% of patients treated with exenatide.
Merck & Co is preparing to file its investigational antitoxin bezlotoxumab in the US, Europe and Canada after late-stage data showed the potential of the drug in preventing the recurrence of Clostridium difficile infection. Bezlotoxumab, a selective, fully-human, monoclonal antibody designed to neutralise C. difficile toxin, could become the first treatment to prevent the bacteria infection from recurring.
Science and Technology
Scientists at Uppsala University are using a research robot to accelerate novel cancer discovery by finding optimal drug combination. Instead of just combining a couple of substances at a time, the system has the ability to handle dozens drugs simultaneously, and the researchers are aiming to raise this to hundreds. “The idea is to gradually refine combinations of substances so that they kill cancer cells without harming healthy cells.” says Dr Claes Andersson, one of the lead scientists in the project.
Medical Devices and Diagnosis News
Wuxi NextCODE will provide genetic testing services for the Children’s Hospital of Fudan University in Shanghai.
Cost and Pricing
UK National Institute for Health and Care Excellence (NICE) recommends Daiichi Sankyo’s antithrombotic Liximia to prevent blood clots in adult patients with heart rhythm disorders as well as for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults. NICE concluded that, at a daily price of £2.10 per patient, the effectiveness ratio was in line with other oral anticoagulants pricing.
US Democratic presidential candidate Hillary Clinton proposed earlier this week a $250 monthly cap on out-of-pocket prescription drugs costs and several other measures such as reducing the 12-year exclusivity given to new biologics under the Biologics Price Competition and Innovation Act to seven years to stop what she called “price gouging” by the pharmaceutical industry. Clinton’s comments came after the New York Times reported how, Turing Pharmaceuticals, a startup company raised the price of the 62-year-old Daraprim, for the treatment of toxoplasmosis, from $13.50 a tablet to $750, an increase of more than 5000%. Biopharmaceutical companies have long faced similar criticism for steadily raising prices of their prescription drugs in the US, often by jumps of 10% or even more.
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood expressed opposition to Hillary Clinton's plan for reducing the costs of drugs and allow the importation of prescription drugs. "The proposal released today by the Clinton campaign would do irreparable harm to the nation's health innovation system," Greenwood said. He also noted that the provisions Clinton announced "have been proposed many times in the past and have always been rebuffed on a bipartisan basis because of the widely recognized fact that they are simply bad ideas for patients."
Amid the drug pricing brouhaha in the U.S. all over the week, Andrew Hill a researcher at the University of Liverpool told Reuters that he conducted a study showing Americans are paying up to three times higher prices for cancer drugs than their counterparts in Europe. For instance, Roche's lung cancer drug Tarceva carries a U.S. price of $79,000, compared with $26,000 to $29,000 in a selection of Western European nations, Hill found. Novartis’ leukemia drug Gleevec runs $106,000 in the U.S. compared with $29,000 to $35,000 in Europe. Tykerb the breast cancer drug Novartis has a U.S. list price of $74,000, compared with $35,000 in Europe. That puts U.S. prices at up to three and a half times those in Europe.
Novartis launches Novartis Access, an initiative for low-income countries whereby a portfolio of 15 of its medicines will be offered to healthcare providers for just $1 per drug per month. The treatments – both patented and generic – are geared towards treating chronic diseases such as diabetes, cardiovascular diseases, respiratory illnesses, as well as breast cancer, will be offered to governments, NGO’s and other public healthcare providers. The Novartis Access programme will be rolled out first in Kenya, Ethiopia and Vietnam, with plans to expand to 30 countries in the coming years.
Miscellaneous
In a U.S. Senate testimony, Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER) at the U.S. FDA, said that biosimilar interchangeability must rest upon “bulletproof” science. The exchanges were most intense between Woodcock and Sen. Elizabeth Warren (D-MA), who was particularly concerned about the delay in FDA's release of a number of guidance documents, particularly on interchangeability and labeling. "We have to get the science right. We can't have problems with the first biosimilars out of the block," Woodcock told Warren. Woodcock added that the remaining guidance documents that have yet to be issued are mostly tied to policy, rather than scientific issues. She also said FDA can't provide any specific dates for when the guidelines will be issued or when the draft guidelines will be finalized because of the complicated authorization process.
Bioevents
- 15th Annual Biotech in Europe Forum for Global Partnering & Investment on September 29-30 in Basel (Switzerland)
- Innovation Days on October 5-6 in Paris (France)
- FierceBiotech Executive Summitt on October 12 in London (UK)
- BIO Japan on October 13-16 in Yokohama (Japan)
- BIO Latin America on October 14-16 in Rio de Janeiro (Brazil)
- BIO Investor Forum on October 20-21 in San Francisco (USA)
- BIO Europe 2015 on November 2-4 in Munich (Germany)
- Biofit 2015 on December 1-2 in Strasbourg (France)
Author: Jean-Claude Muller, Special Advisor at I&IR, jcm@btobioinnovation.com
Discover our services in Marketing & Business Development:
See All News
See other Biopharmaceutical News
see other Pharma & Biotech events in 2015
Last News
- Alzheimer’s disease : Beyond the beta amyloid hypothesis
- Un monde posteuropéen : déjà une réalité ?
- PIB, Budget, Dépenses : Une mise au point.
Events
News archives
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012